Samenvatting Management Life Sciences Innovations - €5,89   In winkelwagen

Samenvatting

Samenvatting Management Life Sciences Innovations

Samenvatting van de volgende artikelen: Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8(12), 959-968. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3), 191-200. Lo, A., & Pisano, G. (2016). Lessons from Hollywood: A new approach to funding R&D. MIT Sloan Management Review, 57(2), 47. Edmondson, A. C., Bohmer, R. M., & Pisano, G. P. (2001). Disrupted routines: Team learning and new technology implementation in hospitals. Administrative Science Quarterly, 46(4), 685-716. Metcalfe, J. S., James, A., & Mina, A. (2005). Emergent innovation systems and the delivery of clinical services: The case of intra-ocular lenses. Research Policy, 34(9), 1283-1304. Pisano, G.P. (2006) Chapter 5: The autonomy of a science-based business. In: Science business – the promise, the reality, and the future of biotech. Harvard Business School Press, Boston. Lehoux, P., Daudelin, G., Williams-Jones, B., Denis, J. L., & Longo, C. (2014). How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs. Research Policy, 43(6), 1025-1038. Willemstein, L., van der Valk, T., & Meeus, M. T. (2007). Dynamics in business models: An empirical analysis of medical biotechnology firms in the Netherlands. Technovation, 27(4), 221-232. Steinberg, D., Horwitz, G., & Zohar, D. (2015). Building a business model in digital medicine. Nature biotechnology, 33(9), 910-920. Sim, I. (2019). Mobile Devices and Health. New England Journal of Medicine, 381(10), 956-968. Boon, W.P.C. Universitair medisch centra als innovatiehubs. In: Boon, W.P.C. & Horlings, E. (2013) Kenniscoproductie voor de grote maatschappelijke vraagstukken. Rathenau Instituut, Den Haag. Christensen, C.M. (2009) Disrupting the hospital business model. In: The innovator’s prescription. McGraw-Hill, New York. Stolk, P. (2013). Background Paper 8.1: Public Private Partnerships. Retrieved from: Aerts, C., Sunyoto, T., Tediosi, F., & Sicuri, E. (2017). Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. Arora, A., Fosfuri, A., & Gambardella, A. (2001) Markets for technology and their implications for corporate strategy. Industrial and corporate change, 10(2), 419- 451. Hopkins, M.M., P.A. Crane, P. Nightingale, C. Baden-Fuller (2013) Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Industrial and Corporate Change. Stuart, T.E., S.Z. Ozdemir, W.W. Ding (2007) Vertical alliance networks: the case of university-biotechnology-pharmaceutical alliance chains. Research Policy 36, 477-498. Powell, W. W., Koput, K. W., & Smith-Doerr, L. (1996). Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology. Administrative science quarterly, 116-145. Smits, R. E., & Boon, W. P. (2008). The role of users in innovation in the pharmaceutical industry. Drug Discovery Today, 13(7), 353-359. Gittelman, M. (2016). The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery. Research Policy, 45(8), 1570-1585. Blind, K. (2004) Chapter 2: A Conceptual Framework to Analyse the Relationship Between Innovation and Regulation. Pp. 3-16. In: New Products and Services: Analysis of Regulations Shaping New Markets. Fraunhofer Institute, Karlsruhe. Hansen, A. (2001). Biotechnology regulation: Limiting or contributing to biotech development?. New Genetics and Society, 20(3), 255-271. Carroll, A. B., & Shabana, K. M. (2010). The business case for corporate social responsibility: a review of concepts, research and practice. International Journal of Management Reviews, 12(1), 85-105. Schurman, R. (2004). Fighting “Frankenfoods”: Industry opportunity structures and the efficacy of the anti-biotech movement in Western Europe. Social Problems, 51(2), 243-268.

Voorbeeld 4 van de 50  pagina's

notermanslode

Voordelen van het kopen van samenvattingen bij Stuvia op een rij:

Verzekerd van kwaliteit door reviews

Verzekerd van kwaliteit door reviews

Stuvia-kopers hebben meer dan 450.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!

Snel en makkelijk kopen

Snel en makkelijk kopen

Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.

Focus op de essentie

Focus op de essentie

Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!

5,89
  • (0)
  Kopen